207 related articles for article (PubMed ID: 36442353)
1. Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis inhibitor.
He LN; Fu S; Ma H; Chen C; Zhang X; Li H; Du W; Chen T; Jiang Y; Wang Y; Wang Y; Zhou Y; Lin Z; Yang Y; Huang Y; Zhao H; Fang W; Zhang H; Zhang L; Hong S
ESMO Open; 2022 Dec; 7(6):100630. PubMed ID: 36442353
[TBL] [Abstract][Full Text] [Related]
2. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
[TBL] [Abstract][Full Text] [Related]
3. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
4. Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy.
He LN; Zhang X; Li H; Chen T; Chen C; Zhou Y; Lin Z; Du W; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
Front Oncol; 2020; 10():621329. PubMed ID: 33552993
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
Ayers KL; Mullaney T; Zhou X; Liu JJ; Lee K; Ma M; Jones S; Li L; Redfern A; Jappe W; Liu Z; Goldsweig H; Yadav KK; Hahner N; Dietz M; Zimmerman M; Prentice T; Newman S; Veluswamy R; Wisnivesky J; Hirsch FR; Oh WK; Li SD; Schadt EE; Chen R
Oncologist; 2021 Jul; 26(7):e1226-e1239. PubMed ID: 33829580
[TBL] [Abstract][Full Text] [Related]
6. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
7. CD8
Duchemann B; Naigeon M; Auclin E; Ferrara R; Cassard L; Jouniaux JM; Boselli L; Grivel J; Desnoyer A; Danlos FX; Mezquita L; Caramella C; Marabelle A; Besse B; Chaput N
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131864
[TBL] [Abstract][Full Text] [Related]
8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
9. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
10. Very high PD-L1 expression as a prognostic indicator of overall survival among patients with advanced non-small cell lung cancer receiving anti-PD-(L)1 monotherapies in routine practice.
Shah M; Hubbard RA; Mamtani R; Marmarelis ME; Hennessy S
Pharmacoepidemiol Drug Saf; 2022 Oct; 31(10):1121-1126. PubMed ID: 35670103
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
12. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
Lang D; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Akbari K; Granitz M; Hutarew G; Kaiser B; Greil R; Lamprecht B
Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203
[TBL] [Abstract][Full Text] [Related]
13. The prediction potential of neutrophil-to-lymphocyte ratio for the therapeutic outcomes of programmed death receptor-1/programmed death ligand 1 inhibitors in non-small cell lung cancer patients: A meta-analysis.
Huang Y; Shen A
Medicine (Baltimore); 2020 Aug; 99(34):e21718. PubMed ID: 32846790
[TBL] [Abstract][Full Text] [Related]
14. Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy.
He LN; Fu S; Zhang X; Hu Q; Du W; Li H; Chen T; Chen C; Jiang Y; Zhou Y; Lin Z; Yang Y; Huang Y; Zhao H; Fang W; Zhang L; Hong S
Lung Cancer; 2021 Aug; 158():1-8. PubMed ID: 34087538
[TBL] [Abstract][Full Text] [Related]
15. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.
Cantini L; Pecci F; Hurkmans DP; Belderbos RA; Lanese A; Copparoni C; Aerts S; Cornelissen R; Dumoulin DW; Fiordoliva I; Rinaldi S; Aerts JGJV; Berardi R
Eur J Cancer; 2021 Feb; 144():41-48. PubMed ID: 33326868
[TBL] [Abstract][Full Text] [Related]
16. The maximum tumor growth rate predicts clinical outcomes of patients with small-cell lung cancer undergoing first-line chemotherapy plus immune-checkpoint inhibitor therapy.
Chen X; Chen X; Liu T; Zhou T; Chen G; Zhou H; Huang Y; Fang W; Yang Y; Zhou N; Chen L; Mo S; Zhang L; Zhao Y
Cancer Med; 2023 Apr; 12(7):8122-8133. PubMed ID: 36629288
[TBL] [Abstract][Full Text] [Related]
17. Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer.
Miyawaki T; Kenmotsu H; Mori K; Miyawaki E; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Harada H; Endo M; Ohde Y; Takahashi K; Takahashi T
Clin Lung Cancer; 2020 Sep; 21(5):e405-e414. PubMed ID: 32205040
[TBL] [Abstract][Full Text] [Related]
18. Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression.
Stinchcombe TE; Miksad RA; Gossai A; Griffith SD; Torres AZ
Clin Lung Cancer; 2020 Sep; 21(5):389-394.e3. PubMed ID: 32409266
[TBL] [Abstract][Full Text] [Related]
19. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
[TBL] [Abstract][Full Text] [Related]
20. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]